Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has announced the successful completion of its human clinical study GLP-1-H25-5. The study compared oral capsules of DehydraTECH-liraglutide to the injected Saxenda®-branded liraglutide. Partial results from the study are now available and indicate a pronounced reduction in adverse events associated with the oral DehydraTECH-liraglutide. Lexaria has demonstrated reductions in adverse events across all three major GLP-1 drugs: liraglutide, semaglutide, and tirzepatide, in distinct clinical human studies. Currently, Lexaria is seeking a pharmaceutical partner to support an FDA-registered oral alternative to the existing injectable GLP-1 brands.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.